Proceso de atención al paciente con urticaria aguda y crónica. Documento de consenso de la sección territorial andaluza de la Academia Española de Dermatología y Venereología

Ruiz‐Villaverde, Ricardo; Moreno‐Ramírez, D.; Galán‐Gutiérrez, Manuel; Troya, M. de; Reyes‐Alcázar, Víctor; Alcalde, M.; García, Emilio Ignacio; Linares, M.; Martínez, L.; Pulpillo, A.; Suárez, C.; Vélez, Antonio; García‐Lora, E.; Torres, A.

doi:10.1016/j.ad.2015.11.005

Cited by 3 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CIE10 code was included, it was also searched by the code: L50.1 and the following treatments: cyclosporine and/or omalizumab. Although cyclosporine has no indication according to the technical data sheet for the treatment of UC, in Andalusia there is an authorization for its use after the failure of antihistamines 7. For this reason, many clinicians use it despite the guidelines of clinical practice as the third line of treatment when there is refractoriness at a quadruple dose of anti-H1, as established in the latest guidelines for urticaria.…”

mentioning

confidence: 99%

Prevalence of chronic urticaria refractory to antihistamines in Andalucia, Spain

Pereyra‐Rodriguez

Gutiérrez

Armario‐Hita

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Chronic urticaria (CU) has a devastating effect on the quality of life of patients who suffer from it. The objective of this study is to determine the prevalence of severe chronic spontaneous urticaria (CSU) in adults in eight health areas in Andalucía. A retrospective observational study from January 2019 to December 2019 was conducted with the participation of seven reference hospitals that were analyzed, including a total reference population of 3 159 001 individuals ≥18 years. The analysis was carried out on the characteristics of the population and the estimated prevalence. In total, 369 patients with a diagnosis of CSU refractory to antagonist of histamine were registered. We have found a prevalence of refractory patients of 0.0012% (95% CI 0.0010%-0.0013), ranging from 0.006% to 0.02%. The present study has helped to describe the prevalence and characteristics of patients with severe urticarial. The prevalence is lower than previously reported. We have observed differences between hospital areas. There will be a new line of research at the national level to help improve the identification of patients with CSU.

show abstract

mentioning

confidence: 99%